Erythropoietin ameliorates hyperglycemia in type 1-like diabetic rats

Niu, Ho‐Shan; Chang, Chin-Hong; Niu, Chiang‐Shan; Cheng, Juei‐Tang; Lee, Kung-Shing

doi:10.2147/dddt.s105867

Cited by 9 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is believed to represent the impaired antiapoptotic action of EPO on proerythroblasts. Possible causes of this EPO hyporesponsiveness include systemic inflammation and microvascular damage in the bone marrow [ 12 , 13 , 14 ]. In the present study, the effectiveness of erythropoiesis seemed to be reduced due to the inflammatory status that prevails in diabetes.…”

Section: Discussionmentioning

confidence: 99%

“…The reason why iron level was adequate but not effectively incorporated in the synthesis of new erythrocytes would lie in the presence of inflammatory-induced alterations in erythropoiesis. The chronic inflammatory status inherent to diabetes mellitus is being widely agreed in the scientific community as responsible for alterations in the synthesis and the presence of resistance to EPO [ 12 , 13 , 14 ]. The linear inverse correlation found between the circulating level of CRP and hemoglobin ( r = −0.605, p < 0.01) supports the previous comments.…”

Section: Discussionmentioning

confidence: 99%

“…Diabetes is a disease with an inflammatory component [ 10 , 11 ]. This fact conditions the appearance of a non-ferropenic anemic state in diabetic patients mainly due to two mechanisms: erythropoietin (EPO) hyposecretion and hyporesponsiveness [ 12 , 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vanadium Decreases Hepcidin mRNA Gene Expression in STZ-Induced Diabetic Rats, Improving the Anemic State

et al. 2021

View full text Add to dashboard Cite

Diabetes is a disease with an inflammatory component that courses with an anemic state. Vanadium (V) is an antidiabetic agent that acts by stimulating insulin signaling. Hepcidin blocks the intestinal absorption of iron and the release of iron from its deposits. We aim to investigate the effect of V on hepcidin mRNA expression and its consequences on the hematological parameters in streptozotocin-induced diabetic Wistar rats. Control healthy rats, diabetic rats, and diabetic rats treated with 1 mgV/day were examined for five weeks. The mineral levels were measured in diet and serum samples. Hepcidin expression was quantified in liver samples. Inflammatory and hematological parameters were determined in serum or whole blood samples. The inflammatory status was higher in diabetic than in control rats, whereas the hematological parameters were lower in the diabetic rats than in the control rats. Hepcidin mRNA expression was significantly lower in the V-treated diabetic rats than in control and untreated diabetic rats. The inflammatory status remained at a similar level as the untreated diabetic group. However, the hematological profile improved after the V-treatment, reaching similar levels to those found in the control group. Serum iron level was higher in V-treated than in untreated diabetic rats. We conclude that V reduces gene expression of hepcidin in diabetic rats, improving the anemic state caused by diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vanadium Decreases Hepcidin mRNA Gene Expression in STZ-Induced Diabetic Rats, Improving the Anemic State

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A number of studies in recent years have demonstrated an association between increased ESA exposure and reduced levels of blood glucose in various species of animals, including rats, pigs, and mice [15-18]. Our own studies in mice demonstrated that mice either exposed to EPO by injection, or constitutively expressing high EPO levels, had less fat than nonexposed control mice and had lower serum glucose levels [19].…”

Section: Introductionmentioning

confidence: 99%

Erythropoietin Treatment Is Associated with Decreased Blood Glucose Levels in Hematologic Patients

et al. 2020

View full text Add to dashboard Cite

Background: Erythroid stimulating agents (ESAs) have pleiotropic effects, and in animal and human studies those exposed to high erythropoietin had lower blood glucose. Objective: To determine the association between ESA and glucose in anemia-treated patients with myelodysplastic syndromes (MDS) or multiple myeloma (MM). Patients and Methods: Patients’ glucose levels were compared while on to while off ESA, and all served as their own controls. To test the association between ESA and blood glucose, we employed a linear mixed model, accounting for variability in the number of measurements for each patient. Results: Charts of 20 patients were reviewed. Mean age was 77 ± 9.8 years (range 50–91). Thirteen patients had MDS, and 8 had MM (1 with both). Glucose (mean ± standard error of the mean) was 116.38 ± 5.21 mg/dL without ESA, as opposed to 105.64 ± 5.11 mg/dL with ESA (p < 0.0001). The 3 diabetic and 5 steroid-treated patients also demonstrated reduced glucose by approximately 19 mg/dL with ESA (p = 0.003 and p = 0.0001, respectively). There was no difference in collective hemoglobin levels between the 2 groups. Conclusion: ESA treatment for anemia is associated with lower blood glucose in hematologic patients. In those who also have diabetes mellitus, ESA might contribute to glucose control, and even to hypoglycemia. Glucose monitoring is thus advised. Further studies with both diabetic and nondiabetic patients are needed to clarify this association and underlying mechanisms.

show abstract

Potential use of transgenic domestic pigs expressing recombinant human erythropoietin in diabetes translation research

Baek

Chung

Kim

et al. 2018

Animal Cells and Systems

View full text Add to dashboard Cite

Recently, diabetes mellitus (DM) has shown rapid global increases with about five million deaths annually. Animal models are imperative to understand disease mechanisms and develop diagnostic, preventive, and therapeutic interventions in translational research. Rodent and mini-pig models have been established and widely used for DM research. However, domestic pig models are limited in spite of advantages such as pharmacokinetic and physiopathological availability. This study examines the potential use of domestic pigs expressing recombinant human erythropoietin (rhEPO) as disease and therapeutic response models for DM. We previously generated transgenic pigs ( n = 16, EPO Tg) in which rhEPO was expressed and circulated in all organs. Thirty-two pigs, including 16 controls, were fed high fat (HF) diets for 42 weeks. Subsequently, blood samples for chemical and metabolic analysis were collected after fasting for 24 h and glucose loading for oral glucose tolerance tests (OGTTs). We found increased activation of the PI3 K/Akt signaling pathway under hypoxic conditions after rhEPO treatment, and HF diet-inducible-obesity in the EPO Tg and control pigs. OGTTs showed lower fasting glucose levels in the EPO Tg pigs than in controls before and after the HF diet, suggesting that rhEPO may affect glucose concentrations. Insulin and C-peptide concentrations responded slowly to glucose administration and returned to initial levels after 2 h. The blood test results suggest that EPO might affect metabolic and chemical components such as glucose, high-density lipoprotein, glucagon, triglyceride, and free fatty acid. Our findings support the use of rhEPO transgenic domestic pigs as model animals for translational DM research.

show abstract

Erythropoietin ameliorates hyperglycemia in type 1-like diabetic rats

Cited by 9 publications

References 40 publications

Vanadium Decreases Hepcidin mRNA Gene Expression in STZ-Induced Diabetic Rats, Improving the Anemic State

Vanadium Decreases Hepcidin mRNA Gene Expression in STZ-Induced Diabetic Rats, Improving the Anemic State

Erythropoietin Treatment Is Associated with Decreased Blood Glucose Levels in Hematologic Patients

Potential use of transgenic domestic pigs expressing recombinant human erythropoietin in diabetes translation research

Contact Info

Product

Resources

About